Chacon-Cruz Enrigue, Rivas-Landeros R M, Volker-Soberanes M L
Pediatric Infectious Diseases Service, Hospital General de Tijuana, Tijuana Baja-California, Paseo Centenario S/N, Zona Rio, Tijuana, Baja-California, ZC 22010, Mexico.
Microbiology Laboratory, Hospital General de Tijuana, Tijuana Baja-California, Mexico.
Ther Adv Vaccines. 2014 Nov;2(6):155-8. doi: 10.1177/2051013614547199.
In May 2012, universal vaccination with the 13-valent pneumococcal conjugate vaccine (PCV-13) was introduced for all children in the Tijuana region of Mexico, with a coverage of 80%.
Between October 2005 and September 2013 active surveillance was undertaken for all invasive pneumococcal diseases (IPDs) in children admitted to the Tijuana General Hospital.
Following PCV-13 implementation, there was a 75% reduction in overall IPD, and no cases of serotype 19A, pneumococcal meningitis, and pneumococcal-associated deaths.
These results are the first to show the effectiveness of PCV-13 in Mexico.
2012年5月,墨西哥蒂华纳地区所有儿童开始普遍接种13价肺炎球菌结合疫苗(PCV-13),接种率为80%。
2005年10月至2013年9月,对蒂华纳总医院收治的儿童所有侵袭性肺炎球菌疾病(IPD)进行了主动监测。
实施PCV-13疫苗接种后,总体IPD减少了75%,且未出现19A血清型、肺炎球菌脑膜炎及肺炎球菌相关死亡病例。
这些结果首次表明PCV-13在墨西哥的有效性。